{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:31:20Z","timestamp":1773016280290,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neuropsychopharm Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore the optimal dose of blonanserin transdermal patch (BNS\u2010P) based on baseline psychiatric symptomatic characteristics during acute schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A post hoc cluster analysis was conducted using data from a 6\u2010week randomized, double\u2010blind, placebo\u2010controlled study of BNS\u2010P (40 or 80\u2009mg\/day) in acute schizophrenia. We classified patients into three clusters based on baseline psychiatric symptoms. Efficacy was assessed using the change from baseline to week 6 in the PANSS total score. Safety was assessed by the incidence of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 577 patients, three clusters were identified, characterized by severe psychiatric (Cluster\u2010S;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009122), predominant negative (Cluster\u2010N;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009191), and predominant positive (Cluster\u2010P;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009264) symptoms. In Cluster\u2010P, both BNS\u2010P 40 and 80\u2009mg\/day reduced PANSS total score significantly more than placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036, effect size\u2009=\u20090.342;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, effect size\u2009=\u20090.687, respectively). In Cluster\u2010S and \u2010N, only BNS\u2010P 80\u2009mg\/day reduced PANSS total score significantly more than placebo (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045, effect size\u2009=\u20090.497;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034, effect size\u2009=\u20090.393, respectively). The effect size was greater at 80\u2009mg\/day than at 40\u2009mg\/day across all clusters. The most common treatment\u2010emergent adverse events were akathisia and skin\u2010related adverse events in all clusters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BNS\u2010P exhibited a dose\u2010dependent antipsychotic effect in all clusters, particularly highlighting its efficacy in patients with predominant positive symptoms, even at lower doses. These findings provide novel and valuable insights for determining BNS\u2010P dose tailoring to individual symptomatic characteristics in real\u2010world practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/npr2.12490","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:39:24Z","timestamp":1729471164000},"page":"784-791","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-4033","authenticated-orcid":false,"given":"Yoshiteru","family":"Takekita","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Faculty of Medicine Kansai Medical University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Medical Science, Sumitomo Pharma Co., Ltd  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[{"name":"Medical Science, Sumitomo Pharma Co., Ltd  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Data Science, Sumitomo Pharma Co., Ltd  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Koshikawa","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Faculty of Medicine Kansai Medical University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-7272","authenticated-orcid":false,"given":"Masaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Faculty of Medicine Kansai Medical University  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,10,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"e_1_2_12_3_1","volume-title":"Practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2021"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-015-0605-1"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12193"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"e_1_2_12_7_1","unstructured":"National Institute for Health and Care Excellence (NICE).Psychosis and schizophrenia in adults: prevention and management. (Clinical guideline [CG178]). [cited 2024 Feb 16]. Available from:https:\/\/www.nice.org.uk\/guidance\/cg178\/evidence\/full\u2010guideline\u2010490503565"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00171-2"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.15406\/jpcpy.2014.01.00023"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0025"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.06.060"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291721004153"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852921000043"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11202620-000000000-00000"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S34433"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2019.07.055"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00692-6"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.04.032"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02354306"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","unstructured":"UmargonoE SusenoJE GunawanSKV.K\u2010means clustering optimization using the elbow method and early centroid determination based\u2010on mean and median. Proceedings of the international conferences on Information system and technology;2019: SCITEPRESS\u2014Science and Technology Publications.","DOI":"10.5220\/0009908402340240"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patrec.2009.09.011"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2017.10.014"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp006"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.4.514"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.10.4.515"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa071"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30060-0"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-018-0869-3"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115104"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31820e4818"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-016-4382-y"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy004"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05698-3"},{"issue":"11","key":"e_1_2_12_36_1","first-page":"1153","article-title":"Safety of antipsychotic pharmacotherapy for schizophrenia: a review of clinical trials and post\u2010marketing surveillance studies conducted in Japan","volume":"24","author":"Inagaki A","year":"2021","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.03.015"}],"container-title":["Neuropsychopharmacology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/npr2.12490","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/npr2.12490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:37:08Z","timestamp":1773013028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/npr2.12490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/npr2.12490"],"URL":"https:\/\/doi.org\/10.1002\/npr2.12490","archive":["Portico"],"relation":{},"ISSN":["2574-173X","2574-173X"],"issn-type":[{"value":"2574-173X","type":"print"},{"value":"2574-173X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,20]]},"assertion":[{"value":"2024-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}